Our proprietary financial instrument
Our proprietary financial instrument releases new cash flow from public companies’, institutions’ and privately held underutilized assets.
The Enhanced cash flow is used…
to pay cash dividends to Strategic Partner asset holders…
and
to acquire positions in new life sciences companies.
This “zero cash outlay” venture capital model lets Strategic Partners profit regardless of the new companies’ performance.